Actively Recruiting
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Led by Samsung Bioepis Co., Ltd. · Updated on 2026-05-11
149
Participants Needed
3
Research Sites
223 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
CONDITIONS
Official Title
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refusal of standard therapy, or no standard therapy available
You will not qualify if you...
- Presence of spinal cord compression or clinically active central nervous system metastases
- Presence of leptomeningeal disease
- History of thromboembolic or clinically significant bleeding events
- Significant cardiovascular disease
- Active autoimmune disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Research Site
Scottsdale, Arizona, United States, 85258
Actively Recruiting
2
Research Site
Fairfax, Virginia, United States, 22031
Actively Recruiting
3
Research Site
Adelaide, Australia
Actively Recruiting
Research Team
S
Samsung Bioepis
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here